Tempest Therapeutics, Inc.
TPST-2003
relapsed/refractory multiple myeloma (rrMM)
Resolved
157days ago
Phase 2 readout · Jan 31, 2026
What's at stake
Phase 2 trial results for TPST-2003 in relapsed/refractory multiple myeloma (rrMM) are due Jan 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“100% complete response (CR) rate among all six efficacy evaluable patients as of the January 31, 2026 data cutoff”